Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita
Shahinaz M. Gadalla(Division of Cancer Epidemiology and Genetics), Sharon A. Savage(National Institutes of Health), E. Anders Kolb(Alfred I. duPont Hospital for Children), H. Joachim Deeg(University of Washington), Gèrard Socié(Hôpital Saint-Louis), Éric Deconinck(European Union), Frederick D. Goldman(University of Alabama at Birmingham), José Sánchez de Toledo Codina(Hospital Materno-Infantil), Stella M. Davies(Cincinnati Children's Hospital Medical Center), Reuven Or(Hebrew University of Jerusalem), Alok Srivastava(Aichi Medical University), Kirsten M. Williams(National Institutes of Health), Carmem Sales‐Bonfim(Hospital de Clínicas Universidade Federal do Paraná), Mary Eapen(Medical College of Wisconsin), Blanche P. Alter(University of North Carolina at Chapel Hill), Joseph H. Antin(Texas Oncology), Jeanette Carreras(Medical College of Wisconsin), Joanne Kurtzberg(Duke University), Jakub Tolar(University of Minnesota), Wing Leung(University of Tennessee Health Science Center), Shalini Shenoy(St. Louis Children's Hospital), Anders Fasth(University of Gothenburg), Robert A. Krance(Baylor College of Medicine), Mouhab Ayas(King Faisal Specialist Hospital & Research Centre), Neelam Giri(Division of Cancer Epidemiology and Genetics), Philip S. Rosenberg(National Cancer Institute), Ardeshir Ghavamzadeh(Tehran University of Medical Sciences), Jeffrey Davis(BC Children's Hospital), Reggie Duerst(Lurie Children's Hospital), Carol M. Richman(University of California, Davis), Prasad Bodhi(Rainbow Babies & Children's Hospital)
Cited by 130
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k